You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

VORICONAZOLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Voriconazole, and what generic alternatives are available?

Voriconazole is a drug marketed by Amneal Pharms, Hainan Poly, Novel Labs Inc, Rising, Almaject, Aspiro, Eugia Pharma, Gland Pharma Ltd, Meitheal, Norvium Bioscience, Sandoz Inc, Slate Run Pharma, UBI, Xellia Pharms Aps, Zydus Pharms, Ajanta Pharma Ltd, Aurobindo Pharma Ltd, Cadila, Chartwell Rx, Epic Pharma Llc, Glenmark Pharms Ltd, Mylan Pharms Inc, Prinston Inc, and Teva Pharms. and is included in twenty-six NDAs.

The generic ingredient in VORICONAZOLE is voriconazole. There are fourteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the voriconazole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Voriconazole

A generic version of VORICONAZOLE was approved as voriconazole by MYLAN PHARMS INC on April 22nd, 2010.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VORICONAZOLE?
  • What are the global sales for VORICONAZOLE?
  • What is Average Wholesale Price for VORICONAZOLE?
Summary for VORICONAZOLE
Drug patent expirations by year for VORICONAZOLE
Drug Prices for VORICONAZOLE

See drug prices for VORICONAZOLE

Recent Clinical Trials for VORICONAZOLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Post Graduate Institute of Medical Education and Research, ChandigarhPhase 3
Gilead SciencesPhase 1
RenJi HospitalPhase 4

See all VORICONAZOLE clinical trials

Medical Subject Heading (MeSH) Categories for VORICONAZOLE
Paragraph IV (Patent) Challenges for VORICONAZOLE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VFEND Oral Suspension voriconazole 40 mg/mL 021630 1 2010-10-08
VFEND For Injection voriconazole 200 mg/vial 021267 1 2008-09-12
VFEND Tablets voriconazole 50 mg and 200 mg 021266 1 2008-04-14

US Patents and Regulatory Information for VORICONAZOLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rising VORICONAZOLE voriconazole TABLET;ORAL 206762-001 May 24, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan Pharms Inc VORICONAZOLE voriconazole TABLET;ORAL 090547-001 Apr 22, 2010 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rising VORICONAZOLE voriconazole TABLET;ORAL 206762-002 May 24, 2016 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan Pharms Inc VORICONAZOLE voriconazole TABLET;ORAL 090547-002 Apr 22, 2010 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for VORICONAZOLE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pfizer Europe MA EEIG Vfend voriconazole EMEA/H/C/000387
Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Authorised no no no 2002-03-19
Accord Healthcare S.L.U. Voriconazole Accord voriconazole EMEA/H/C/002669
Voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged two years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Voriconazole Accord should be administered primarily to patients with progressive, possibly life-threatening infections.
Authorised yes no no 2013-05-16
Hikma Farmaceutica (Portugal) S.A. Voriconazole Hikma (previously Voriconazole Hospira) voriconazole EMEA/H/C/003737
Voriconazole is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of candidaemia in non-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT)recipients.
Authorised yes no no 2015-05-27
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.